Drugs / KAZ954
last change Sep 2023 re-read 2 minutes ago

KAZ954

Developed for
cancer
Investigated by
Novartis Pharmaceuticals

Trials 1 · a red edge is where a trial was stopped

2020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 0 NCT04237649 Feb 2020 → Sep 2023 cancer Novartis Pharmaceuticals Terminated No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as KAZ954 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04237649